all of the patients in examples below have been endoscopically diagnosed as interstitial cystitis , and have not shown a response to the bladder hydrodistension procedure which is the only approved treatment in japan , but are still suffering from pain . more specifically , they are patients who are suffering prolonged pain even on the injection of 4 % xylocaine alone or 20 ml of 4 % xylocaine + 100 ml amikacin + 300 mg saxizon . treatment contents involve an injection of about 8 cc mucosta ( registered trademark ) eye drops in a syringe into the bladder through a catheter using 28 packages of the eye drops ( for 1 hour or more ). the chief complaint was cystalgia on urine storage and urethral pain in conjunction with non - bacterial chronic prostatitis . he received the bladder hydrodistension procedure at certain municipal hospital , but complained strong recurrent cystalgia . accordingly the above treatment was performed on jul . 24 and 31 in 2013 . as a result , pain has disappeared to date . bladder ulcer also has been ameliorated as easily observed by visual inspection on endoscope photographs ( fig1 and 2 ). no adverse effect was observed . seventy nine years old ( female ), first visit on apr . 2 , 2012 . the treatment as described above was performed 6 times , i . e ., on jul . 26 , 29 , 30 and 31 , and aug . 2 and 3 in 2013 . as a result , pain has disappeared to date . bladder ulcer also has been ameliorated as easily observed by visual inspection on endoscope photographs ( fig3 and 4 ). no adverse effect was observed . the treatment as described above was performed on jul . 29 , 2013 . as a result , pain has disappeared to date . no adverse effect was observed . as described above , the treatment described above all clearly showed efficacy for interstitial cystitis which was considered as intractable disease until that time , and for which there was no effective treatment method . furthermore , therapeutic effects were also observed for non - bacterial chronic prostatitis that occurred in combination . note that diagnosis and bladder injections can be performed by using the foregoing invention which the present inventors have previously invented . therefore , it was possible to perform diagnosis and treatment without causing stress to a patient . in addition , before treatment , treatment contents were explained to the patients , and written consent was also obtained . in addition , experiments were performed for studying effects of the present invention on cystitis using a rat model of chronic cystitis . to 12 - week old male sd rats , cyclophosphamide ( 150 mg / kg ) was intraperitoneally administered under isoflurane anesthetization . immediately after that , rebamipide ( 1 mm or 10 mm , 300 μl ) or vehicle was injected into the bladder , and the rats were held in the supine position for 1 hour . ( 1 ) after two days , conscious cystometrography was performed ( the saline perfusion flow rate : 0 . 04 ml / min ) was performed . ( 2 ) after two days , the bladder was removed , and h & amp ; e stained to score the degree of inflammation ( 3 ) tnfα , il - 6 and il - 1β which are inflammatory cytokines in bladder tissue were measured by rt - pcr , and an inflammation marker , mpo , was measured by elisa . ( 1 ) in the cystometry studies , a reduced urination interval was observed in the cyp group ( 10 . 7 ± 0 . 7 min ) as compared with the control ( 22 . 4 ± 2 . 3 min ) while a prolonged urination interval was observed dose - dependently in the rebamipide group ( the 1 mm group ; 14 . 4 ± 2 . 1 min and the 10 mm group : 21 . 1 ± 2 . 5 min ). ( 2 ) submucosal edema and invasive inflammatory cells were significantly higher in the cyp group , and significantly reduced in the rebamipide group . ( 3 ) the levels of tnfα , il - 6 , il - 1β and mpo in the bladder tissue were significantly higher in the cyp group , and their increase was suppressed in the rebamipide group . bladder inflammation was suppressed by injecting rebamipide into the bladder , and a prolonged urination interval was observed . as described above , the present invention is effective for not only interstitial cystitis but other cystitis and chronic nonbacterial prostatitis , and also effective for lower urinary tract diseases including chronic cystitis , prostatic hyperplasia , chronic nonbacterial prostatitis , prostatitis , prostatism , bladder neck contracture and overactive bladder . therefore , the present invention provides a new therapeutic agent and a new treatment method for these diseases .
a method of treating a condition chosen from the group consisting of interstitial cystitis , cystitis , chronic nonbacterial prostatitis , chronic cystitis , prostatic hyperplasia , prostatitis , prostatism , bladder neck contracture , bladder inflammation , and overactive bladder by administering an amount of rebamipide or a pharmaceutically acceptable salt thereof to a human .